Representational image
New Delhi: Sun Pharma Advanced Research Company (SPARC), the pharma research and drug discovery arm of Sun Pharma, on Friday reported widening of standalone net loss to Rs 36.41 crore for the first quarter that ended on June 30.
SPARC had posted a net loss of Rs 1.65 crore for the corresponding period of the previous fiscal year, it said in a filing to the BSE.
Standalone total income from operations of the company for the quarter under consideration also decreased to Rs 21.48 crore as against Rs 43.44 crore a year ago.
Shares in Sun Pharma Advanced Research Company ended 3.70 per cent lower at Rs 361.80 apiece on the BSE, whose benchmark Sensex index finished up 0.56 per cent.
SPARC had posted a net loss of Rs 1.65 crore for the corresponding period of the previous fiscal year, it said in a filing to the BSE.
Standalone total income from operations of the company for the quarter under consideration also decreased to Rs 21.48 crore as against Rs 43.44 crore a year ago.
Shares in Sun Pharma Advanced Research Company ended 3.70 per cent lower at Rs 361.80 apiece on the BSE, whose benchmark Sensex index finished up 0.56 per cent.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices, Watch Business News Live and Latest Stories — On NDTV Profit.